Literature DB >> 15333042

Atrial fibrillation and thrombosis: immunohistochemical differences between in situ and embolized thrombi.

W E Wysokinski1, W G Owen, D N Fass, D D Patrzalek, L Murphy, R D McBane.   

Abstract

BACKGROUND/
OBJECTIVE: Thromboembolism secondary to atrial fibrillation accounts for approximately one-fourth of all strokes. Although considerable resources have been targeted to pharmacologic prophylaxis, neither the cellular nor the biochemical composition of atrial thrombi is known. Quantitative immunohistochemistry was undertaken to define the composition of atrial thrombi and to explore morphological differences between atrial appendage thrombi and those that embolize. PATIENTS/
METHODS: Serial sections of thrombi obtained during valve replacement surgery or embolectomy from 22 patients with atrial fibrillation were stained with antibodies against fibrin, integrin beta3, or tissue factor and analyzed with NIH-image.
RESULTS: Thrombi showed distinct regions staining for either fibrin or platelets and on average, the fibrin-rich regions predominated (P < 0.0001). The platelet content of embolized thrombi was nearly twice that of atrial thrombi (P = 0.02). Non-staining amorphous material comprised nearly half of atrial thrombi in situ, but was rare in embolized thrombi (P < 0.001). Tissue factor colocalized to areas rich in platelets and granulocytes.
CONCLUSIONS: The abundance of fibrin relative to platelets underscores the enhanced efficacy of warfarin prophylaxis in clinical trials. The finding of tissue factor localized to platelet-leukocyte clusters suggests its blood-borne origin. Compositional differences between in situ and embolized thrombi suggest directions for investigating propensity for embolization.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15333042     DOI: 10.1111/j.1538-7836.2004.00899.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  19 in total

Review 1.  Antithrombotic treatment in atrial fibrillation.

Authors:  G Y H Lip; C J Boos
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

2.  Stroke prevention in atrial fibrillation--things can only get better.

Authors:  Gregory Y H Lip; Timothy Watson
Journal:  Br J Clin Pharmacol       Date:  2007-06-19       Impact factor: 4.335

3.  The hydraulic permeability of blood clots as a function of fibrin and platelet density.

Authors:  A R Wufsus; N E Macera; K B Neeves
Journal:  Biophys J       Date:  2013-04-16       Impact factor: 4.033

Review 4.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

5.  A Platelet Function Modulator of Thrombin Activation Is Causally Linked to Cardiovascular Disease and Affects PAR4 Receptor Signaling.

Authors:  Benjamin A T Rodriguez; Arunoday Bhan; Andrew Beswick; Peter C Elwood; Teemu J Niiranen; Veikko Salomaa; David-Alexandre Trégouët; Pierre-Emmanuel Morange; Mete Civelek; Yoav Ben-Shlomo; Thorsten Schlaeger; Ming-Huei Chen; Andrew D Johnson
Journal:  Am J Hum Genet       Date:  2020-07-09       Impact factor: 11.025

6.  Relationship between thrombus attenuation and different stroke subtypes.

Authors:  J M Niesten; I C van der Schaaf; G J Biessels; A E van Otterloo; T van Seeters; A D Horsch; M J A Luitse; Y van der Graaf; L J Kappelle; W P T M Mali; B K Velthuis
Journal:  Neuroradiology       Date:  2013-06-21       Impact factor: 2.804

Review 7.  Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update.

Authors:  Matteo Nicola Dario Di Minno; Antonella Tufano; Walter Ageno; Paolo Prandoni; Giovanni Di Minno
Journal:  Intern Emerg Med       Date:  2011-04-02       Impact factor: 3.397

Review 8.  Tissue factor in coagulation: Which? Where? When?

Authors:  Saulius Butenas; Thomas Orfeo; Kenneth G Mann
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-07-10       Impact factor: 8.311

9.  Systemic Embolic Events (SEE) in Atrial Fibrillation: SEEing Embolic Risk More Clearly.

Authors:  Neal A Chatterjee; Steven A Lubitz
Journal:  Circulation       Date:  2015-07-29       Impact factor: 29.690

10.  Association between P-selectin levels and left atrial blood stasis in patients with nonvalvular atrial fibrillation.

Authors:  W E Wysokinski; K P Cohoon; R M Melduni; M Mazur; N Ammash; T Munger; E Konik; T McLeod; Izabeal Gosk-Bierska; R D McBane
Journal:  Thromb Res       Date:  2018-10-10       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.